Item 2.02. Results of Operations and Financial Condition.

On May 12, 2022, Integrated Biopharma, Inc. (the "Company") issued a press release announcing its financial results for the fiscal quarter ended March 31, 2022. A copy of the press release is furnished as Exhibit 99.1 hereto and is hereby incorporated by reference into this Item 2.02.

The information in this Item 2.02 (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 5.05. Amendments to or changes to the Company's Code of Ethics.

On May 11, 2022, the Company updated its Code of Conduct and Ethics Policy in order to include new sections, including, but not limited to Foreign Corrupt Practices and Anti-Bribery Provisions as well as updating other sections contained within the policy. The updated policy is filed as Exhibit 14.1 hereto and is hereby incorporated by reference into this Item 5.05.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit 99.1 relating to Item 2.02 shall be deemed to be furnished, and not filed:




14.1     Code of Conduct and Ethics
99.1     Press Release dated May 12, 2022
104    Cover Page Interactive Data File (embedded within the Inline XBRL document)































                                      -1-

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses